DOI: https://doi.org/10.17650/2949-5857-2024-14-4-55-62

The evolving role of surgery in multimodal cancer treatment: a comprehensive review

Kirolos Eskandar
Diakonie Klinik Mosbach, Germany

Contacts: Kirolos Eskandar *kiroloss.eskandar@gmail.com*

The landscape of cancer treatment has evolved significantly with the integration of multimodal approaches, wherein surgery plays a pivotal role. This comprehensive review examines the dynamic role of surgical interventions within the framework of multimodal cancer therapy, highlighting historical advancements, innovative surgical techniques, and their synergistic effects with other treatment modalities. We explore preoperative, intraoperative, and postoperative considerations, emphasizing patient selection, technological innovations, and multidisciplinary collaboration. Through case studies and clinical trials, we illustrate the efficacy and challenges of combining surgery with chemotherapy, radiotherapy, and emerging therapies. Addressing controversies and future trends, this review underscores the necessity of personalized and precision medicine in enhancing patient outcomes. The insights provided aim to guide clinicians and researchers in optimizing surgical strategies within the multifaceted landscape of cancer care.

Keywords: surgical oncology, multimodal cancer treatment, precision surgery, neoadjuvant therapy, personalized medicine

For citation: Kirolos Eskandar. The evolving role of surgery in multimodal cancer treatment: a comprehensive review. Khirurgiya i onkologiya = Surgery and Oncology 2024;14(4):55–62.
DOI: https://doi.org/10.17650/2949-5857-2024-14-4-55-62

Возрастающая роль хирургии в мультимодальном лечении рака: комплексный обзор

Киролос Эскандар

Diakonie Klinik Mosbach, Germany

Контакты: Киролос Эскандар *kiroloss.eskandar@gmail.com*

Схема лечения рака претерпела существенные изменения благодаря интеграции мультимодальных подходов, в которых ключевую роль играет хирургия. В настоящем подробном обзоре исследуется динамическая роль хирургических вмешательств в рамках многомодальной терапии рака, представлены исторические достижения, инновационные хирургические методы и их синергетические эффекты с другими методами лечения.
Особое внимание уделяется предоперационным, интраоперационным, и послеоперационным аспектам: выбору пациента, технологическим инновациям и мультидисциплинарному сотрудничеству. На примере анализа клинических случаев и клинических исследований проиллюстрирована эффективность хирургического вмешательства, а также проблемы сочетания хирургии с химиотерапией, лучевой терапией и новыми методами лечения. В обзоре рассмотрены спорные вопросы и будущие тенденции, подчеркивается необходимость персонализированной и точной медицины для улучшения результатов лечения пациентов. Представленные идеи помогут клиницистам и исследователям оптимизировать хирургические стратегии в условиях обширного поля онкологической помощи.

Ключевые слова: хирургическая онкология, мультимодальное лечение рака, прецизионная хирургия, неоадъювантная терапия, персонализированная медицина

Для цитирования: Kirolos Eskandar. The evolving role of surgery in multimodal cancer treatment: a comprehensive review. Khirurgiya i onkologiya = Surgery and Oncology 2024;14(4):55–62. (На англ.).
DOI: https://doi.org/10.17650/2949-5857-2024-14-4-55-62

Introduction

The management of cancer has evolved significantly over the past few decades, shifting from single-modality treatments to more comprehensive approaches that integrate multiple therapeutic strategies. This shift, known as multimodal cancer treatment, encompasses a combination of surgery, chemotherapy, radiation therapy, immunotherapy, and targeted therapies. These advancements aim to improve survival rates, reduce recurrence, and enhance the quality of life for cancer patients [1].

Surgery has historically been a cornerstone of cancer treatment. It plays a critical role not only in the diagnosis and staging of cancer but also in its definitive treatment, especially for solid tumors. the role of surgery has expanded with the advent of new techniques and technologies, making it possible to perform minimally invasive procedures, improve precision in tumor resection, and integrate surgical interventions more effectively with other treatment modalities. For instance, the implementation of robotic-assisted surgery has allowed for greater precision and reduced recovery times, thereby facilitating the integration of surgery into broader treatment plans.

The importance of surgery in cancer care cannot be overstated. It often serves as the primary treatment modality for many cancers, particularly in early stages where complete resection can be curative. Moreover, surgery can significantly impact the efficacy of other treatments. For example, tumor debulking can enhance the effectiveness of chemotherapy and radiation therapy by reducing the tumor burden and improving drug delivery and radiation penetration [2].

This review aims to provide a comprehensive overview of the evolving role of surgery in the context of multimodal cancer treatment. It will explore the integration of surgical techniques with other therapies, highlight advancements in surgical technology, and discuss the outcomes and benefits of multimodal approaches. the review is structured to first present an overview of the background and current practices in multimodal cancer treatment, followed by detailed discussions on the synergy between surgery and other treatment modalities, innovations in surgical techniques, and the impact of these integrated approaches on patient outcomes [3].

Methodology

A systematic approach was utilized for this literature review, adhering to the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines to gather relevant articles and studies in Emergency medicine's critical cases. a thorough search was conducted in reputable databases, including PubMed, Google Scholar, Scopus, and Web of Science, using specific keywords such as "Surgical Oncology", "Multimodal Cancer Treatment," "Precision Surgery," "Neoadjuvant Therapy," "Personalized Medicine" to ensure comprehensive coverage of pertinent literature.

The inclusion criteria for the studies were as follows: (1) publications in English, (2) studies focusing specifically on surgery, and (3) studies reporting on multimodal cancer treatment. Initially, 131 articles were retrieved from the databases. After a meticulous examination to eliminate duplicate references, 43 unique articles met the inclusion criteria. These articles underwent rigorous evaluation through a comprehensive assessment of their titles, abstracts, and full texts, confirming their alignment with the established inclusion criteria and warranting their inclusion in the review.

To provide a clear overview of the study selection process, the PRISMA flow diagram is included below (fig. 1), illustrating the number of records identified, screened, and included in the review, along with reasons for exclusion at each stage.

Historical perspective

The field of surgical oncology has evolved remarkably since its inception, reflecting significant advancements in medical knowledge and technology. Early surgical efforts to treat cancer date back to ancient civilizations, but it was not until the 19th century that surgery began to be recognized



Fig. 1. *Illustrates the PRIMSA flow diagram*

as a viable option for cancer treatment. The establishment of antiseptic techniques and anesthesia revolutionized surgery, allowing for more extensive and safer procedures [4].

One of the earliest milestones in surgical oncology was the development of radical mastectomy by William Stewart Halsted in the late 1800s. Halsted's methodical approach and emphasis on the thorough removal of cancerous tissue set the standard for surgical procedures for many years [5]. This era was characterized by the belief that more extensive surgery would lead to better outcomes, an approach that dominated surgical oncology for much of the 20th century.

The mid-20th century saw the integration of surgery with other treatment modalities, marking a pivotal shift in cancer care. the advent of radiation therapy and chemotherapy provided new avenues for treatment, reducing the need for excessively radical surgeries. For example, the introduction of adjuvant chemotherapy and radiation in the treatment of breast cancer allowed for less invasive surgeries, such as lumpectomy, to achieve outcomes comparable to more radical approaches [6].

In recent decades, the concept of multimodal treatment has gained prominence, emphasizing the integration of surgery with systemic therapies and radiation to optimize patient outcomes. This approach has been facilitated by advances in imaging, minimally invasive surgical techniques, and a better understanding of cancer biology. For instance, the use of neoadjuvant chemotherapy, which is administered before surgery, has been shown to shrink tumors, making them more resectable and improving surgical outcomes [7].

Minimally invasive techniques, such as laparoscopic and robotic surgery, have further revolutionized the field by reducing recovery times and postoperative complications. These advancements have made surgery a less daunting prospect for patients and have expanded the potential for surgical intervention in more complex cases [8].

Furthermore, the role of surgery has evolved from merely a curative intervention to a component of palliative care in advanced cancer cases. Surgical procedures are now frequently performed to alleviate symptoms and improve the quality of life for patients with metastatic or inoperable tumors [9].

Surgical techniques and innovations

Recent advances in surgical techniques and innovations have significantly transformed the landscape of oncological surgery. a notable development is the advent of minimally invasive surgery (MIS), which includes both laparoscopic and robotic approaches. Minimally invasive techniques offer numerous benefits, such as reduced postoperative pain, shorter hospital stays, faster recovery times, and improved cosmetic outcomes. the introduction of the da Vinci robotic system has further enhanced the precision of these procedures by providing better visualization and dexterity, which are crucial in complex oncological surgeries. Studies have demonstrated the efficacy of robotic surgery in various oncologic procedures, showing comparable, if not superior, outcomes to traditional open surgeries in terms of oncologic safety and patient recovery [10, 11].

The use of image-guided techniques has also seen substantial advancements. Technologies such as intraoperative ultrasound, fluorescence imaging, and augmented reality have improved the surgeon's ability to precisely locate tumors and critical anatomical structures. These technologies are particularly beneficial in surgeries involving complex anatomies, such as liver and pancreatic resections. Image-guided surgery enhances the accuracy of tumor resections, potentially reducing the rates of incomplete resections and local recurrences [12].

The integration of precision surgery techniques with personalized medicine is another groundbreaking development. Personalized surgical approaches are tailored based on the patient»s genetic profile, tumor characteristics, and response to previous treatments. This strategy aims to optimize surgical outcomes by ensuring that the chosen surgical technique and extent of resection are best suited to the individual patient's condition. Advances in genomics and molecular biology have enabled the identification of biomarkers that predict response to surgical interventions, facilitating more informed surgical planning [13].

Multimodal treatment strategies

Multimodal cancer treatment strategies have revolutionized oncology, integrating surgery, chemotherapy, radiotherapy, immunotherapy, and targeted therapy to optimize patient outcomes. These strategies employ a combination of treatments tailored to the specific characteristics of the patient's cancer, enhancing efficacy and reducing recurrence rates.

Multimodal treatment approaches involve the coordinated use of various therapeutic modalities to target cancer from multiple angles. Surgery often serves as the initial step to remove primary tumors, creating an opportunity for adjuvant therapies to eradicate residual cancer cells. Chemotherapy and radiotherapy are frequently used in conjunction with surgery to address micrometastases and reduce tumor size preoperatively, making surgical resection more effective [14].

The advent of immunotherapy and targeted therapies has further expanded the potential of multimodal treatments. Immunotherapy, which leverages the body's immune system to fight cancer, can be combined with traditional treatments to enhance their effectiveness. For example, immune checkpoint inhibitors have shown promise in increasing the sensitivity of tumors to radiotherapy and chemotherapy, thereby improving overall response rates [15]. Targeted therapies, which focus on specific molecular targets associated with cancer, can be used alongside other treatments to improve precision and reduce systemic toxicity [16].

Case studies highlight the success of multimodal approaches. For instance, patients with advanced colorectal cancer have benefited from a combination of surgical resection, chemotherapy, and targeted therapy with agents

like bevacizumab, which inhibits angiogenesis. This integrated strategy has resulted in prolonged survival and improved quality of life [17]. Similarly, in breast cancer treatment, the use of surgery followed by chemotherapy, radiotherapy, and hormone therapy has significantly reduced recurrence rates and improved survival outcomes [16].

Preoperative considerations

Preoperative considerations in multimodal cancer treatment involve several critical aspects, including the role of neoadjuvant therapies, patient selection criteria, and multidisciplinary team planning.

Neoadjuvant therapies, such as chemotherapy, radiotherapy, and increasingly, immunotherapy, are administered before surgical intervention to shrink tumors, enhance resectability, and potentially improve overall survival outcomes. the efficacy of neoadjuvant therapy has been demonstrated in various cancer types. For instance, studies have shown that neoadjuvant PD-1 blockade can significantly improve outcomes in resectable lung cancer, with notable trials such as the KEYNOTE-811 emphasizing dual PD-1 and HER2 blockade in HER2-positive gastric cancer [18]. Similarly, the use of neoadjuvant immune checkpoint inhibitors has shown promise in high-risk resectable melanoma and other cancers [19, 20].

Patient selection criteria for surgery in the context of multimodal treatment are complex and multifactorial. Factors such as tumor stage, patient comorbidities, and overall functional status must be considered. Risk assessment tools and scoring systems, like the ACS NSQIP Geriatric Surgery Guidelines, aid in evaluating perioperative risks and tailoring interventions to individual patient profiles [21]. Preoperative patient education also plays a pivotal role, with studies indicating that well-informed patients experience better postoperative recovery and reduced anxiety [22].

Multidisciplinary team planning is essential for optimal cancer care. This approach involves surgeons, medical oncologists, radiologists, pathologists, and other specialists collaborating to devise a comprehensive treatment plan. Such collaboration ensures that each aspect of the patient»s care is considered, from the initial diagnosis through treatment and postoperative follow-up. This team-based approach has been shown to improve clinical outcomes and patient satisfaction [23].

By integrating these preoperative considerations into a cohesive treatment strategy, healthcare providers can enhance the efficacy of surgical interventions within the broader context of multimodal cancer therapy. This multidisciplinary, patient-centered approach is crucial for achieving the best possible outcomes for cancer patients.

Intraoperative considerations

Intraoperative considerations are critical to optimizing surgical outcomes in cancer treatment. Advanced techniques such as sentinel lymph node biopsy (SLNB) and tumor margin assessment play pivotal roles in enhancing surgical precision and patient outcomes. SLNB, for instance, helps in accurately staging cancer and determining the extent of lymph node involvement without the need for extensive lymph node dissections, thereby reducing the risk of complications and improving recovery times [24]. Tumor margin assessment is equally crucial, ensuring that all malignant tissues are removed during surgery, which is essential for minimizing the risk of cancer recurrence.

The incorporation of intraoperative imaging and navigation technologies has revolutionized surgical oncology. These technologies provide real-time, high-resolution images that guide surgeons during procedures, enhancing accuracy and minimizing damage to surrounding healthy tissues. For example, intraoperative MRI and CT scans allow for precise localization and excision of tumors, ensuring complete removal while preserving vital structures [25]. Additionally, fluorescence-guided surgery, which uses fluorescent dyes that bind to cancer cells, enables surgeons to visualize and remove tumors more effectively.

Moreover, the role of intraoperative navigation systems, such as robotic-assisted surgery, cannot be overstated. These systems offer enhanced dexterity, precision, and control, leading to improved surgical outcomes, particularly in complex and minimally invasive procedures. Robotic systems like the da Vinci Surgical System have been shown to reduce surgical trauma, lower complication rates, and shorten recovery times compared to traditional open surgery [26]. These innovations not only improve the technical aspects of surgery but also significantly impact patient recovery and overall prognosis.

Postoperative care and complications

Postoperative care in cancer surgery is critical for ensuring optimal recovery, managing complications, and enhancing the overall quality of life for patients. Effective postoperative management involves a multifaceted approach that addresses immediate recovery needs, monitors for potential complications, and incorporates long-term rehabilitation strategies.

Postoperative management begins with monitoring and treating common complications. These complications can range from minor issues, such as superficial surgical site infections (SSI), to more severe problems like deep vein thrombosis (DVT) and pulmonary embolism (PE). According to Brigham and Women»s Hospital, early intervention is essential for managing complications such as bleeding, wound infections, and pulmonary complications, which can arise due to insufficient deep breathing exercises post-surgery [27].

Effective pain management is another crucial aspect of postoperative care. the use of various pain relief medications, including nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, and opioids, can significantly enhance patient comfort and expedite recovery. However, it is important to balance pain relief with the risk of potential

side effects, such as nausea, constipation, and, in the case of opioids, the risk of addiction [28].

Postoperative complications have shown trends of both decrease and increase over recent years. For instance, a study by BMC Surgery noted a decline in superficial and deep SSIs, urinary tract infections, and unplanned returns to the operating room from 2012 to 2018. However, complications like organ/space SSIs and sepsis showed an upward trend, highlighting the need for ongoing vigilance and adaptive strategies in postoperative care [28].

Functional recovery and quality of life are paramount in the postoperative phase, especially for cancer patients who often undergo extensive treatments. Morrison-Jones and West emphasize the importance of rapid rescue and enhanced recovery protocols. These protocols aim to minimize the physical and psychological impact of surgery, promote early mobilization, and ensure that patients receive comprehensive support throughout their recovery journey [29].

Intraoperative technologies and techniques also play a role in postoperative outcomes. Advances in imaging and navigation during surgery help ensure precise tumor removal and adequate margin assessment, which can reduce the likelihood of complications and improve recovery trajectories [29].

Surgery in specific cancer types

Surgery plays a critical role in the management of various cancers, with its application and outcomes varying significantly across different cancer types. For common cancers such as breast, colorectal, lung, and prostate cancers, surgery often remains a cornerstone of treatment, either as a primary intervention or as part of a multimodal approach.

In breast cancer, surgical options include lumpectomy and mastectomy, often complemented by sentinel lymph node biopsy to assess the spread of disease. Advances in breast-conserving surgeries have significantly improved cosmetic outcomes without compromising survival rates. Additionally, the integration of neoadjuvant therapies has allowed for more breast conservation in cases initially deemed suitable only for mastectomy [30].

Colorectal cancer surgery has seen notable advancements, particularly with the advent of minimally invasive techniques such as laparoscopic and robotic surgeries. These approaches have reduced postoperative complications and improved recovery times. Furthermore, total mesorectal excision has become a standard for rectal cancer, reducing local recurrence rates and enhancing long-term survival [31].

In lung cancer, surgical resection is primarily reserved for early-stage non-small cell lung cancer (NSCLC). Techniques such as lobectomy and segmentectomy are standard, with video-assisted thoracoscopic surgery (VATS) becoming increasingly popular due to its minimally invasive nature and reduced patient morbidity [32]. the role of surgery in more advanced stages has diminished with the rise of targeted therapies and immunotherapy, which have shown promising results.

Prostate cancer management often involves radical prostatectomy, especially in patients with localized disease. the evolution of robotic-assisted laparoscopic prostatectomy has led to improved precision, reduced blood loss, and faster recovery, making it a preferred method in many centers [33].

Surgery for rare and complex cancers, such as sarcomas or pancreatic cancer, presents unique challenges. These cancers often require highly specialized surgical techniques and a multidisciplinary approach to optimize outcomes. For instance, the complexity of pancreatic cancer surgery, particularly the Whipple procedure, demands high surgical expertise and is usually performed in high-volume centers to ensure the best results [34].

Emerging trends and future directions

Emerging trends and future directions in surgical oncology are being shaped by several transformative advances in genetic and molecular profiling, immunotherapy, and technological innovations. These developments are profoundly influencing surgical decision-making and patient outcomes.

Genetic and molecular profiling are becoming integral to the precision medicine approach in oncology. By analyzing the genetic mutations and molecular characteristics of tumors, clinicians can tailor surgical and therapeutic interventions to individual patient profiles. This approach enhances the precision of surgical procedures and optimizes the selection of adjuvant therapies, improving overall treatment efficacy and patient outcomes [35]. the integration of molecular diagnostics with surgical planning allows for the identification of patients who would benefit from less invasive surgeries or those who require more extensive surgical intervention due to aggressive tumor biology.

Advancements in immunotherapy, particularly checkpoint inhibitors targeting PD-1/PD-L1, are also reshaping the landscape of surgical oncology. Immunotherapies are being increasingly used in combination with surgery to treat various cancers, including melanoma, lung, and bladder cancers. the synergistic effect of combining surgery with immunotherapy can enhance the immune response against residual tumor cells, potentially reducing recurrence rates and improving long-term survival [36]. Ongoing research is exploring the optimal timing and sequencing of these treatments to maximize patient benefits.

In addition to immunotherapy, the role of advanced imaging and navigation technologies is becoming more prominent. Intraoperative imaging techniques, such as real-time MRI and fluorescence-guided surgery, are improving the accuracy of tumor resections. These technologies help surgeons delineate tumor margins more precisely, thereby minimizing the risk of leaving residual cancerous tissue and reducing the likelihood of recurrence [37].

Future research directions in surgical oncology are likely to focus on further integrating these technological and therapeutic advancements into clinical practice. This includes the continued development of minimally invasive

surgical techniques, such as robotic-assisted surgery, which offer the potential for reduced recovery times and improved surgical outcomes. Additionally, the exploration of novel biomarkers and the development of targeted therapies based on genetic and molecular profiling will be crucial in advancing personalized surgical care.

Case studies and clinical trials

The incorporation of surgical interventions within multimodal cancer treatments has significantly evolved, demonstrating the crucial role of surgery in enhancing treatment outcomes. Key clinical trials and case studies provide valuable insights into this integration, underscoring the benefits and challenges associated with various surgical approaches.

One notable clinical trial involved the use of tumor-treating fields (TTFields) for glioblastoma, which highlighted the potential of combining surgery with innovative therapies. TTFields, a non-invasive treatment, showed improved survival rates when used alongside traditional surgical resection, radiotherapy, and chemotherapy [38]. This trial exemplifies the importance of exploring new therapeutic combinations to optimize patient outcomes.

In colorectal cancer, the PRODIGE 7 trial examined the efficacy of cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy (HIPEC). the results indicated that while the addition of HIPEC did not significantly extend overall survival, it did improve disease-free survival in certain patient subsets, emphasizing the need for patient-specific treatment planning [39].

Furthermore, case studies have illustrated innovative surgical approaches in multimodal treatment plans. For instance, a case study on breast cancer patients demonstrated the successful integration of neoadjuvant chemotherapy, followed by breast-conserving surgery and radiotherapy, which resulted in favorable long-term outcomes and reduced recurrence rates [40].

Challenges and controversies

The landscape of surgical oncology is rife with challenges and controversies that reflect the evolving nature of cancer treatment and the ongoing quest for optimal therapeutic strategies. Debates on the extent and timing of surgery in multimodal treatment regimens are particularly prominent. the integration of surgery with chemotherapy, radiotherapy, and other modalities raises questions about the best sequence of treatments to maximize patient outcomes. For instance, the use of neoadjuvant therapies – treatments given before the main surgical intervention – can shrink tumors, making surgery less invasive and more effective. However, determining the precise timing and dosage of these therapies remains contentious, with ongoing research aimed at refining these protocols [41].

Ethical considerations in surgical oncology also present significant challenges. Issues such as informed consent, particularly in the context of experimental treatments or clinical trials, require careful navigation to ensure that patients are fully aware of potential risks and benefits. Moreover, the decision to perform aggressive surgical procedures on patients with advanced or metastatic disease involves weighing the potential for improved quality of life and survival against the risks of surgery and the possibility of limited benefits. This balance is a critical aspect of ethical surgical practice and is constantly being reevaluated as new treatments and technologies emerge [42].

Addressing disparities in access to advanced surgical care is another critical issue. Socioeconomic factors, geographic location, and healthcare infrastructure significantly impact patients' ability to receive cutting-edge surgical treatments. For instance, patients in rural or underserved areas may lack access to specialized surgical oncologists or advanced medical facilities, resulting in delayed diagnoses and suboptimal treatment outcomes. Efforts to bridge these gaps include telemedicine, mobile health units, and policies aimed at increasing healthcare funding and resources in disadvantaged areas. These initiatives are essential for ensuring that all patients, regardless of their background, have access to the best possible cancer care [43].

Conclusion

In conclusion, the evolving role of surgery in multimodal cancer treatment is marked by significant advancements and ongoing challenges. Historical milestones and innovations in surgical techniques, such as minimally invasive and robotic surgery, have revolutionized cancer care, while the integration of precision surgery and image-guided methods underscores the impact of personalized medicine. Multimodal treatment strategies, encompassing chemotherapy, radiotherapy, immunotherapy, and targeted therapy, have demonstrated improved patient outcomes in numerous case studies and clinical trials. Preoperative and intraoperative considerations, including neoadjuvant therapies and advanced imaging technologies, further optimize surgical outcomes. However, debates on the extent and timing of surgery, ethical dilemmas, and disparities in access to care remain pressing issues. As the field progresses, the impact of genetic and molecular profiling, alongside emerging trends in immunotherapy, promises to shape the future of surgical oncology, highlighting the need for continued research and innovation to address these complex challenges and enhance the quality of life for cancer patients.

REFERENCES

1. Carrieri F.A., Smack C., Siddiqui I. et al. Tumor Treating fields: at the crossroads between physics and biology for cancer treatment. Front Oncol 2020;10. https://doi.org/10.3389/fonc.2020.575992
2. Fain S.N. Use of a mechanical suturing apparatus in low colorectal anastomosis. Arch Surg 1975;110(9):1079. https://doi.org/10.1001/archsurg.1975.01360150023004
3. Chang S.S., Bochner B.H., Chou R. et al. Treatment of Non-Metastatic Muscle-Invasive Bladder Cancer: AUA/ASCO/ASTRO/SUO Guideline. J Urol 2017;198(3):552–9. https://doi.org/10.1016/j.juro.2017.04.086
4. Newman L., Fejerman L., Pal T. et al. Breast cancer disparities through the lens of the COVID-19 pandemic. Curr Breast Cancer Rep 2021;13(3):110–2. https://doi.org/10.1007/s12609-021-00419-x
5. Hashimoto N., Rabo C.S., Okita Y. et al. Slower growth of skull base meningiomas compared with non-skull base meningiomas based on volumetric and biological studies. J Neurosurg 2012;116(3):574–80. https://doi.org/10.3171/2011.11.JNS11999
6. Walsh M.T., Couldwell W.T. Management options for cavernous sinus meningiomas. J Neuro-Oncol 2009;92(3):307–16. https://doi.org/10.1007/s11060-009-9824-5
7. Vernooij M.W., Ikram M.A., Tanghe H.L. et al. Incidental findings on brain mri in the general population. N Engl J Med 2007;357(18):1821–8. https://doi.org/10.1056/nejmoa070972
8. Umansky F., Nathan H. The lateral wall of the cavernous sinus. With special reference to the nerves related to it. J Neurosurg 1982;56(2):228–34. https://doi.org/10.3171/jns.1982.56.2.0228
9. Chamoun R., Krisht K.M., Couldwell W.T. Incidental meningiomas. Neurosurg focus 2011;31(6):E19. https://doi.org/10.3171/2011.9.FOCUS11220
10. Lo W.M., Tohme S.T., Geller D.A. Recent advances in minimally invasive liver resection for colorectal cancer liver metastases – a review. Cancers 2022;15(1):142. https://doi.org/10.3390/cancers15010142
11. Miskovic D., Wexner S.D., Stojadinovic A. et al. Robotic colorectal surgery: Where are we now? Surg Endosc 2021;35(2):389–403. https://doi.org/10.1007/s00464-020-07784-x
12. Husarova T., MacCuaig W.M., Dennahy I.S. et al. Intraoperative imaging in hepatopancreatobiliary surgery. Cancers 2023;15(14):3694. https://doi.org/10.3390/cancers15143694
13. Cai H., Wang Y., Qin D. et al. Advanced surgical technologies for lung cancer treatment: Current status and perspectives. Engineered Regeneration 2023;4(4):55–67. https://doi.org/10.1016/j.engreg.2022.12.001
14. Luengo Morato Y., Ovejero Paredes K., Lozano Chamizo L. et al. Recent advances in multimodal molecular imaging of cancer mediated by hybrid magnetic nanoparticles. Polymers 2021;13(17):2989. https://doi.org/10.3390/polym13172989
15. Sharma P., Jhawat V., Mathur P., Dutt R. Innovation in cancer therapeutics and regulatory perspectives. Med Oncol 2022;39(5):76. https://doi.org/10.1007/s12032-022-01677-0
16. Liu J., He S., Luo Y. et al. Tumor-microenvironment-activatable polymer nano-immunomodulator for precision cancer photoimmunotherapy. Adv Mater 2022;34(8):e2106654. DOI: 10.1002/adma.202106654
17. Yang H., Li C., Xie Q. Advances in the use of nanomaterials in tumour therapy: challenges and prospects. Cancer Insight 2023;2(2):37–48. https://doi.org/10.58567/ci02020004
18. Janjigian Y.Y., Kawazoe A., Yañez P. et al. The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3
19. Forde P.M., Chaft J.E., Smith K.N. et al. Neoadjuvant PD-1 blockade in resectable lung cancer. N Engl J Med 2018;378(21):1976–86. https://doi.org/10.1056/NEJMoa1716078
20. Amaria R.N., Reddy S.M., Tawbi H.A. et al. Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nat Med 2018;24(11):1649–54. https://doi.org/10.1038/s41591-018-0197-1
21. Chow W.B., Ko C.Y., Rosenthal R.A., Esnaola N.F. ACS NSQIP / AGS BEST PRACTICE GUIDELINES: Optimal Preoperative Assessment of the Geriatric Surgical Patient. In ACS NSQIP / AGS BEST PRACTICE GUIDELINES: Optimal Preoperative Assessment of the Geriatric Surgical Patient. 2011.
22. Brodersen F., Wagner J., Uzunoglu F.G., Petersen-Ewert C. Impact of preoperative patient education on postoperative recovery in abdominal surgery: a systematic review. World J Surg 2023;47(4):937–47. https://doi.org/10.1007/s00268-022-06884-4
23. Vaquero Roncero L.M., Sánchez Poveda D., Valdunciel García J.J. Perioperative use of angiotensin-converting-enzyme inhibitors and angiotensin receptor antagonists. J Clin Anesth 2017;40:91–8. https://doi.org/10.1016/j.jclinane.2017.04.018
24. De Simone B., Sartelli M., Coccolini F. et al. Intraoperative surgical site infection control and prevention: a position paper and future addendum to WSES intra-abdominal infections guidelines. WJES 2020;15(1):10. https://doi.org/10.1186/s13017-020-0288-4
25. Long D.R., Alverdy J.C., Vavilala M.S. Emerging paradigms in the prevention of surgical site infection: the patient microbiome and antimicrobial resistance. Anesthesiology 2022;137(2):252–62. https://doi.org/10.1097/ALN.0000000000004267
26. Rosa R., Sposato K., Abbo L.M. Preventing surgical site infections: implementing strategies throughout the perioperative continuum. AORN 2023;117(5):300–11. https://doi.org/10.1002/aorn.13913
27. Breast Surgery Postoperative Care – Brigham and Women's Hospital. https://www.brighamandwomens.org/surgery/breast-surgery/post-operative-care#:~:text=At%20Brigham%20and%20Women's%20Hospital,while%20minimizing%20pain%20and%20complications
28. Dencker E.E., Bonde A., Troelsen A. et al. Postoperative complications: an observational study of trends in the United States from 2012 to 2018. BMC Surgery 2021;21(1). https://doi.org/10.1186/s12893-021-01392-z
29. Morrison-Jones V., West M. Post-operative care of the cancer patient: emphasis on functional recovery, rapid rescue, and survivorship. Curr Oncol 2023;30(9):8575–85. https://doi.org/10.3390/curroncol30090622
30. Zhang X., Li H., Wu F. et al. Neoadjuvant chemotherapy combined with breast-conserving surgery in the treatment of triple-negative breast cancer. J Oncol 2022:7847889. https://doi.org/10.1155/2022/7847889
31. Haverkamp D., Redwood D., Roik E. et al. Elevated colorectal cancer incidence among American Indian/Alaska Native persons in Alaska compared to other populations worldwide. Int J Circumpolar Health 2023;82(1):2184749. https://doi.org/10.1080/22423982.2023.2184749
32. Pearson C., Fraser J., Peake M. et al. Establishing population-based surveillance of diagnostic timeliness using linked cancer registry and administrative data for patients with colorectal and lung cancer. Cancer epidemiology 2019;61:111–8. https://doi.org/10.1016/j.canep.2019.05.010
33. Fry A., White B., Nagarwalla D. et al. Relationship between ethnicity and stage at diagnosis in England: a national analysis of six cancer sites. BMJ Open 2023;13(1):e062079. https://doi.org/10.1136/bmjopen-2022-062079
34. Mitchell M. Cancer in the UK: Overview 2024. Cancer Research UK. 2024.
35. Collins D.C., Sundar R., Lim J.S.J., Yap T.A. Towards precision medicine in the clinic: from biomarker discovery to novel therapeutics. Trends Pharmacol Sci 2017;38(1):25–40. https://doi.org/10.1016/j.tips.2016.10.012

36. Yi M., Zheng X., Niu M. et al. Combination strategies with PD-1/PD-L1 blockade: current advances and future directions. Mol Cancer 2022;21(1):28. https://doi.org/10.1186/s12943-021-01489-2
37. Cheng F., Su L., Qian C. Circulating tumor DNA: a promising biomarker in the liquid biopsy of cancer. Oncotarget 2016;7(30):48832–41. https://doi.org/10.18632/oncotarget.9453
38. Guo X., Yang X., Wu J. et al. Tumor-treating fields in glioblastomas: past, present, and future. Cancers 2022:14(15):3669. https://doi.org/10.3390/cancers14153669
39. Witmer H.D.D., Dhiman A., Turaga K.K. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases: Where do we stand? Cancer 2023;129(4):495–502. https://doi.org/10.1002/cncr.34567
40. Volders J.H., Negenborn V.L., Spronk P.E. et al. Breast-conserving surgery following neoadjuvant therapy – a systematic review on surgical outcomes. Breast cancer research and treatment 2018;168(1):1–12. https://doi.org/10.1007/s10549-017-4598-5
41. Parks R., Cheung K.L. Challenges in geriatric oncology – a surgeon's perspective. Curr Oncol 2022;29(2):659–74. https://doi.org/10.3390/curroncol29020058
42. Vakili-Ojarood M., Naseri A., Shirinzadeh-Dastgiri A. et al. Ethical Considerations and Equipoise in Cancer Surgery. Indian J Surg Oncol 2024;15(Suppl 3):363–73. https://doi.org/10.1007/s13193-024-02023-8
43. Albrecht B., Alfano S., Keane H., Yang G. Delivering innovation: 2020 oncology market outlook. McKinsey & Company. 2020 https://www.mckinsey.com/industries/life-sciences/our-insights/delivering-innovation-2020-oncology-market-outlook

ORCID of author/ORCID автора
Kirolos Eskandar: https://orcid.org/0000-0003-0085-3284

Ethics approval and consent to participate. Not applicable.
Одобрение этики и согласие на участие. Неприменимо.

Consent for publication. Not applicable.
Согласие на публикацию. Неприменимо.

Availability of data and material. Data sharing not applicable to this article as no data-sets were generated or analyzed during the current study.
Наличие исходных данных и материалов. Совместное использование данных неприменимо к этой статье, так как во время текущего исследования не было создано или проанализировано ни одного набора данных.

Conflict of interest. The author declares no conflict of interest.
Конфликт интересов. Автор заявляет об отсутствии конфликта интересов.

Funding. The work was performed without external funding.
Финансирование. Работа выполнена без спонсорской поддержки.

Article submitted: 25.07.2024. **Accepted for publication:** 08.10.2024. **Published online:** 28.11.2024.
Статья поступила: 25.07.2024. **Принята к публикации:** 08.10.2024. **Опубликована онлайн:** 28.11.2024.